IRWD News and Press, Ironwood Pharmaceuticals Inc. From 11/03/22

– LINZESS ® (Iinaclotide) EUTRx prescription demand growth in Q3 2022 increased 10% year-over-year – – Ironwood and its partner, AbbVie, plan to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FD...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 3, 2022. Individuals interested in participating in the call should dial (888) 330-2384 (...

Summary Pharmaceuticals and biotechnology have the best value and quality scores. Healthcare providers look undervalued relative to 11-year averages. Other healthcare industries don’t look attractive. Focus on a biotech ETF: GNOM (and why I don’t like it). ...

Summary Today, we are revisiting Ironwood Pharmaceuticals for the first time since April of 2021. The company continues to live off its Lizness franchise and is putting its cash flow to good use in paying down debt and buying back stock. Given that Ironwood Pharmaceuticals sto...

AbbVie ( NYSE: ABBV ) and Ironwood Pharmaceuticals' medicine ( NASDAQ: IRWD ) Linzess met the main and secondary goals of a phase 3 trial in pediatric patients aged six years to 17 years with functional constipation (FC). Linzess (linaclotide) is approv...

– Study met primary and secondary endpoints – – Results add to body of data supporting the safety of linaclotide for this patient population – – There are currently no FDA approved prescription pediatric therapies for Functional Const...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Thursday, September 8, 2022 at 8:00 a.m. ET at the Encore Boston Harbor in Everett, MA. A live webcast of Ironwood’s fireside chat will be ac...

Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. 10 stocks cheaper than their peers in August. This monthly article series shows a dashboa...

Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2022 Earnings Conference Call August 4, 2022 08:30 a.m. ET Company Representatives Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Matt Roache - Direc...

The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation